Search - tctmd.com

Displaying 661 - 680 of 784

Sort: Relevancy | Date

Presentation ACC 2012

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study

Presenter: Laura Mauri

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

Stem Cell Therapy Fails to Show Benefit in Chronic Ischemic Heart Failure

L.A. McKeown

March 24, 2012

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

News Conference News ACC 2012

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

Jason Kahn

March 24, 2012

News Conference News ACC 2012

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

L.A. McKeown

March 24, 2012

Presentation ACC 2012

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

Presenter: Josep Rod?s-Cabau

March 24, 2012

Presentation ACC 2012

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Presenter: Matthew Price

March 24, 2012

Presentation ACC 2012

Economic Impact of Transradial Percutaneous Coronary Intervention

Presenter: David Safley

March 24, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

News Conference News

TEST - COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

Shelley Wood

April 10, 2001

Presentation

test 2 slide - server migration

September 09, 2000

Video

» Conference Wrap-Up

ACC 2026 Day 3 Wrap-Up

March 30, 2026

Video

» Interview

Beyond the Data: CHIP-BCIS3

March 30, 2026

Video

» Interview

Beyond the Data: ORBITA-CTO

March 29, 2026

Video

» Conference Wrap-Up

ACC 2026 Day 2 Wrap-Up

March 29, 2026

Video

» Conference Wrap-Up

ACC 2026 Day 1 Wrap-Up

March 28, 2026

Advertisement

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Stem Cell Therapy Fails to Show Benefit in Chronic Ischemic Heart Failure

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Economic Impact of Transradial Percutaneous Coronary Intervention

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

TEST - COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

test 2 slide - server migration

ACC 2026 Day 3 Wrap-Up

Beyond the Data: CHIP-BCIS3

Beyond the Data: ORBITA-CTO

ACC 2026 Day 2 Wrap-Up

ACC 2026 Day 1 Wrap-Up

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content